A smaller phase 2 trial evaluated the safety and efficacy of durvalumab with concurrent palliative RT in 10 patients with either inoperable or metastatic disease with a minimum of 5% PD-L1 expression across multiple disease sites. Here, CD274 is linked to metastatic neoplasm.